Research Article
Preferential Activity of Petiveria alliacea Extract on Primary Myeloid Leukemic Blast
Table 1
Clinical characteristics of patients with acute leukemia.
| | Novo acute leukemia | | Code | Sex | Age (years) | Type | Subtype | Genetic alteration | % Blast by flow cytometry | Karyotype | Extramedullary infiltration in CNS | Chemotherapy protocol |
| | SC0001 | M | 38 | AML | Acute monoblastic leukemia | — | 25 | Abnormal | Negative | 7 + 3 | | SC0002 | F | 62 | ALL | Common B-ALL | — | 57.1 | Normal | Negative | HyperCVAD | | SC0004 | F | 56 | ALL | Common B-ALL | t(9; 22) (q34.1; q11.2) | 84.7 | Abnormal | Positive | HyperCVAD | | SC0005 | M | 20 | ALL | Cortical T-ALL | — | 95.8 | Normal | Negative | HyperCVAD | | SC0008 | F | 66 | AML | Acute promyelocytic leukemia | t(8; 21) (q22; q22.1) | 89.9 | Abnormal | Negative | 7 + 3 | | SC0009 | F | 58 | MPAL | B/Myeloid MPAL | — | 68.6 | Normal | Negative | HyperCVAD | | SC0010 | M | 66 | AML | AML without maturation | Trisomy 8/NPM1 (-) FLT3 (-) | 61.2 | Abnormal | Negative | 7 + 3 | | SC0011 | M | 55 | ALL | Common ALL-B | — | 96.3 | Normal | Positive | HyperCVAD | | SC0012 | M | 35 | ALL | Common ALL-B | — | 97.2 | Normal | Negative | HyperCVAD | | SC0013 | M | 32 | MPAL | B/T MPAL | — | 96.4 | Normal | Positive | HyperCVAD | | SC0017 | M | 52 | ALL | Pro-B ALL | — | 76 | Normal | Negative | HyperCVAD | | SC0018 | F | 20 | ALL | Common ALL-B | — | 84.6 | Normal | Positive | HyperCVAD | | SC0019 | M | 68 | AML | AML with minimal differentiation | — | 92.1 | Normal | Negative | 7 + 3 | | SC0022 | F | 19 | ALL | Common ALL-B | — | 73 | Normal | Negative | HyperCVAD | | SC0023 | M | 51 | ALL | Common ALL-B | — | 97.6 | Normal | Positive | HyperCVAD | | SC0025 | M | 69 | AML | AML without maturation | NPM1 (-) FLT3 (-) | 76.9 | Normal | Negative | 7 + 3 | | SC0026 | F | 19 | ALL | Pre-B ALL | t(9; 22) (q34.1; q11.2) 84.1 | | Abnormal | Positive | HyperCVAD | | SC0027 | M | 19 | AML | Therapy-related AML | — | 51 | Normal | Negative | 7 + 3 | | SC0030 | F | 69 | AML | AML with myelodysplasia related changes | inv(17) | 90.1 | Abnormal | Negative | 7 + 3 | | SC0032 | F | 23 | ALL | Common ALL-B | Hyperdiploidy | 91 | Normal | Negative | HyperCVAD | | SC0033 | F | 60 | ALL | Pre-T ALL | — | 87.9 | Normal | Negative | HyperCVAD | | SC0035 | F | 22 | AML | AML with maturation | NPM1 (-) FLT3 (-) | 46.6 | Normal | Negative | 7 + 3 | | SC0036 | F | 58 | ALL | Pre-B ALL | t(9; 22) (q34.1; q11.2) | 82.54 | Abnormal | Positive | HyperCVAD | | SC0037 | M | 55 | ALL | Common ALL-B | t(9; 22) (q34.1; q11.2) | 92.3 | Abnormal | Positive | HyperCVAD | | SC0038 | M | 73 | AML | AML with maturation | — | 62.66 | Normal | Negative | 7 + 3 | | SC0040 | F | 66 | AML | AML without maturation | NPM1 (-) FLT3 (-) | 77.6 | Normal | Negative | 7 + 3 | | Relapse leukemia | | SC0013 R | M | 32 | MPAL | B/T MPAL | — | — | Normal | Positive | Idaflag | | SC0015 R | F | 22 | ALL | LLA-B Pre-B | — | 93.2 | Normal | Negative | Idaflag | | SC0018 R | F | 20 | ALL | Common ALL-B | — | 79.2 | Normal | Positive | Idaflag | | SC0019 R | M | 68 | AML | AML with minimal differentiation | — | 95.1 | Normal | Negative | Azacitidine | | SC0034 R | M | 37 | AML | Acute promyelocytic leukemia | APL without PLM-RARa | 78 | Normal | Positive | Arsenic trioxide | | SC0039 R | M | 75 | AML | AML with maturation | — | 22 | Normal | Negative | Azacitidine |
|
|
F : female; M : male; AML : acute myeloid leukemia; ALL : acute lymphoblastic leukemia; MPAL : mixed phenotype acute leukemia; NPM1 : nucleophosmin 1; FLT3 : FMS-like tyrosine kinase 3; PLM-RARa : PML-retinoic acid receptor alpha.
|
